New Drug Approvals

Considerations for Value Preparation for ASCO 2014 Drugs

June 11, 2014 4:07 am

http://www.mmm-online.com/considerations-for-value-preparation-for-asco-2014-drugs/article/354931/

Alan Gray, senior director, oncology commercial strategy group, Kantar Health

As in previous years, ASCO 2014 did not disappoint, revealing exciting data for promising new treatments, especially in the field of immuno-oncology. Other exciting drugs (CDKs) and newer generations of targeted agents for EGFR and ALK mutations continue to advance treatment of

Alan Gray

Considerations for Value Preparation for ASCO 2014 Drugs
Medical Marketing and Media
Other exciting drugs (CDKs) and newer generations of targeted agents for … that are traditionally completed during Phase III of clinical development.